Cargando…

Bisphosphonate use after clinical fracture and risk of new fracture

SUMMARY: Among older adults with a previous fracture, treatment for osteoporosis was initially associated with a higher risk of new fracture. However, the relative risk of new fracture decreased over time, a trend that is consistent with a beneficial effect, as treatment for osteoporosis is prescrib...

Descripción completa

Detalles Bibliográficos
Autores principales: Bergman, J., Nordström, A., Nordström, P.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer London 2018
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5854733/
https://www.ncbi.nlm.nih.gov/pubmed/29397408
http://dx.doi.org/10.1007/s00198-017-4367-7
_version_ 1783306964822917120
author Bergman, J.
Nordström, A.
Nordström, P.
author_facet Bergman, J.
Nordström, A.
Nordström, P.
author_sort Bergman, J.
collection PubMed
description SUMMARY: Among older adults with a previous fracture, treatment for osteoporosis was initially associated with a higher risk of new fracture. However, the relative risk of new fracture decreased over time, a trend that is consistent with a beneficial effect, as treatment for osteoporosis is prescribed to reduce high fracture risks. INTRODUCTION: The purpose of this study was to examine whether bisphosphonate use is associated with a lower risk of new fracture after a clinical fracture in older adults. METHODS: Data were available for 3,329,400 adults in Sweden who were aged ≥ 50 years between 2006 and 2011. During this period, 260,353 sustained a clinical fracture and were naïve to bisphosphonates at the time. Those who subsequently received a bisphosphonate were matched to up to three others on sex, year of birth, and type and year of initial fracture. The final cohort comprised 83,104 adults (26.3% bisphosphonate users). RESULTS: During the period from initial fracture to initiation of bisphosphonate treatment, the incidence rate of any new clinical fracture was higher in those who later became bisphosphonate users than in those who remained nonusers (175.1 vs. 75.9 per 1000 person-years; hazard ratio 2.30, 95% confidence interval 2.19 to 2.41). Similarly, during the first 6 months of treatment, the incidence rate was higher in bisphosphonate users than in nonusers (128.8 vs. 90.2 per 1000 person-years; hazard ratio 1.41, 95% confidence interval 1.32 to 1.51). However, this difference decreased over time: by months 12 to 18, the incidence rate was similar in users and nonusers (59.3 vs. 55.3 per 1000 person-years; hazard ratio 1.03, 95% confidence interval 0.91 to 1.16). CONCLUSIONS: There was a decrease in the relative risk of new fracture during bisphosphonate treatment, a trend that is consistent with a beneficial treatment effect, as bisphosphonates are prescribed to reduce high fracture risks. ELECTRONIC SUPPLEMENTARY MATERIAL: The online version of this article (10.1007/s00198-017-4367-7) contains supplementary material, which is available to authorized users.
format Online
Article
Text
id pubmed-5854733
institution National Center for Biotechnology Information
language English
publishDate 2018
publisher Springer London
record_format MEDLINE/PubMed
spelling pubmed-58547332018-03-22 Bisphosphonate use after clinical fracture and risk of new fracture Bergman, J. Nordström, A. Nordström, P. Osteoporos Int Original Article SUMMARY: Among older adults with a previous fracture, treatment for osteoporosis was initially associated with a higher risk of new fracture. However, the relative risk of new fracture decreased over time, a trend that is consistent with a beneficial effect, as treatment for osteoporosis is prescribed to reduce high fracture risks. INTRODUCTION: The purpose of this study was to examine whether bisphosphonate use is associated with a lower risk of new fracture after a clinical fracture in older adults. METHODS: Data were available for 3,329,400 adults in Sweden who were aged ≥ 50 years between 2006 and 2011. During this period, 260,353 sustained a clinical fracture and were naïve to bisphosphonates at the time. Those who subsequently received a bisphosphonate were matched to up to three others on sex, year of birth, and type and year of initial fracture. The final cohort comprised 83,104 adults (26.3% bisphosphonate users). RESULTS: During the period from initial fracture to initiation of bisphosphonate treatment, the incidence rate of any new clinical fracture was higher in those who later became bisphosphonate users than in those who remained nonusers (175.1 vs. 75.9 per 1000 person-years; hazard ratio 2.30, 95% confidence interval 2.19 to 2.41). Similarly, during the first 6 months of treatment, the incidence rate was higher in bisphosphonate users than in nonusers (128.8 vs. 90.2 per 1000 person-years; hazard ratio 1.41, 95% confidence interval 1.32 to 1.51). However, this difference decreased over time: by months 12 to 18, the incidence rate was similar in users and nonusers (59.3 vs. 55.3 per 1000 person-years; hazard ratio 1.03, 95% confidence interval 0.91 to 1.16). CONCLUSIONS: There was a decrease in the relative risk of new fracture during bisphosphonate treatment, a trend that is consistent with a beneficial treatment effect, as bisphosphonates are prescribed to reduce high fracture risks. ELECTRONIC SUPPLEMENTARY MATERIAL: The online version of this article (10.1007/s00198-017-4367-7) contains supplementary material, which is available to authorized users. Springer London 2018-02-03 2018 /pmc/articles/PMC5854733/ /pubmed/29397408 http://dx.doi.org/10.1007/s00198-017-4367-7 Text en © The Author(s) 2018 Open Access This article is distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 International License (http://creativecommons.org/licenses/by-nc/4.0/), which permits any noncommercial use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made.
spellingShingle Original Article
Bergman, J.
Nordström, A.
Nordström, P.
Bisphosphonate use after clinical fracture and risk of new fracture
title Bisphosphonate use after clinical fracture and risk of new fracture
title_full Bisphosphonate use after clinical fracture and risk of new fracture
title_fullStr Bisphosphonate use after clinical fracture and risk of new fracture
title_full_unstemmed Bisphosphonate use after clinical fracture and risk of new fracture
title_short Bisphosphonate use after clinical fracture and risk of new fracture
title_sort bisphosphonate use after clinical fracture and risk of new fracture
topic Original Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5854733/
https://www.ncbi.nlm.nih.gov/pubmed/29397408
http://dx.doi.org/10.1007/s00198-017-4367-7
work_keys_str_mv AT bergmanj bisphosphonateuseafterclinicalfractureandriskofnewfracture
AT nordstroma bisphosphonateuseafterclinicalfractureandriskofnewfracture
AT nordstromp bisphosphonateuseafterclinicalfractureandriskofnewfracture